The combination of dimethoxycurcumin with DNA methylation inhibitor enhances gene re-expression of promoter-methylated genes and antagonizes their cytotoxic effect

References

• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28; PMID:12042769; http://dx.doi.org/10.1038/nrg962
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20:2429-40; PMID:12011120; http://dx.doi.org/10.1200/JCO.2002.04.117
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247-52; PMID:17962618; http://dx.doi.org/10.1634/theoncologist.12-10-1247
   PubMed Web of Science ®Google Scholar
• Fandy TE. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem 2009; 16:2075-85; PMID:19519382; http://dx.doi.org/10.2174/092986709788612738
   PubMed Web of Science ®Google Scholar
• Kotecha R, Takami A, Espinoza JL. Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. Oncotarget; 7(32):52517-52529; PMID:27232756; http://dx.doi.org/10.18632/oncotarget.9593
   PubMedGoogle Scholar
• Aggarwal BB, Yuan W, Li S, Gupta SC. Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. Mol Nutr Food Res 2013; 57:1529-42; PMID:23847105; http://dx.doi.org/10.1002/mnfr.201200838
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 2013; 169:1672-92; PMID:23425071; http://dx.doi.org/10.1111/bph.12131
   PubMed Web of Science ®Google Scholar
• Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. Aaps J 2013; 15:195-218; PMID:23143785; http://dx.doi.org/10.1208/s12248-012-9432-8
   PubMed Web of Science ®Google Scholar
• Tamvakopoulos C, Dimas K, Sofianos ZD, Hatziantoniou S, Han Z, Liu ZL, Wyche JH, Pantazis P. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res 2007; 13:1269-77; PMID:17317839; http://dx.doi.org/10.1158/1078-0432.CCR-06-1839
   PubMed Web of Science ®Google Scholar
• Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, Li PK, Lin J, Fuchs JR, Marcucci G, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett 2009; 19:706-9; PMID:19112019; http://dx.doi.org/10.1016/j.bmcl.2008.12.041
   PubMed Web of Science ®Google Scholar
• Shu L, Khor TO, Lee JH, Boyanapalli SS, Huang Y, Wu TY, Saw CL, Cheung KL, Kong AN. Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. Aaps J 2011; 13:606-14; PMID:21938566; http://dx.doi.org/10.1208/s12248-011-9300-y
   PubMed Web of Science ®Google Scholar
• Hassan HE, Carlson S, Abdallah I, Buttolph T, Glass KC, Fandy TE. Curcumin and dimethoxycurcumin induced epigenetic changes in leukemia cells. Pharm Res 2015; 32:863-75; PMID:25186441; http://dx.doi.org/10.1007/s11095-014-1502-4
   PubMed Web of Science ®Google Scholar
• Parashar G, Capalash N. Promoter methylation-independent reactivation of PAX1 by curcumin and resveratrol is mediated by UHRF1. Clin Exp Med 2015; 16(3):471-478; PMID:26081871; http://dx.doi.org/10.1007/s10238-015-0366-1
   PubMed Web of Science ®Google Scholar
• Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, Gore SD. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 2008; 27:3615-23; PMID:18223691; http://dx.doi.org/10.1038/sj.onc.1211018
   PubMed Web of Science ®Google Scholar
• Brinkman AB, Gu H, Bartels SJ, Zhang Y, Matarese F, Simmer F, Marks H, Bock C, Gnirke A, Meissner A, et al. Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk. Genome Res 2012; 22:1128-38; PMID:22466170; http://dx.doi.org/10.1101/gr.133728.111
   PubMed Web of Science ®Google Scholar
• Statham AL, Robinson MD, Song JZ, Coolen MW, Stirzaker C, Clark SJ. Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Res 2012; 22:1120-7; PMID:22466171; http://dx.doi.org/10.1101/gr.132076.111
   PubMed Web of Science ®Google Scholar
• Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 2007; 13:4225-32; PMID:17634552; http://dx.doi.org/10.1158/1078-0432.CCR-06-2762
   PubMed Web of Science ®Google Scholar
• Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001; 61:1327-33; PMID:11245429
   PubMed Web of Science ®Google Scholar
• Vijayaraghavalu S, Dermawan JK, Cheriyath V, Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm 2013; 10:337-52; PMID:23215027; http://dx.doi.org/10.1021/mp3004622
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, et al. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics 2015; 7:29; PMID:25806091; http://dx.doi.org/10.1186/s13148-015-0065-5
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440-6; PMID:20068163; http://dx.doi.org/10.1158/0008-5472.CAN-09-1947
   PubMed Web of Science ®Google Scholar
• Yu J, Peng Y, Wu LC, Xie Z, Deng Y, Hughes T, He S, Mo X, Chiu M, Wang QE, et al. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PLoS One 2013; 8:e55934; PMID:23457487; http://dx.doi.org/10.1371/journal.pone.0055934
   PubMed Web of Science ®Google Scholar
• Chen CQ, Yu K, Yan QX, Xing CY, Chen Y, Yan Z, Shi YF, Zhao KW, Gao SM. Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases. Carcinogenesis 2013; 34:1442-9; PMID:23430957; http://dx.doi.org/10.1093/carcin/bgt070
   PubMed Web of Science ®Google Scholar
• Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279:51163-71; PMID:15383533; http://dx.doi.org/10.1074/jbc.M409024200
   PubMed Web of Science ®Google Scholar
• Zhang T, Cooper S, Brockdorff N. The interplay of histone modifications - writers that read. EMBO Rep 2015; 16:1467-81; PMID:26474904; http://dx.doi.org/10.15252/embr.201540945
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr 2011; 6:93-108; PMID:21516481; http://dx.doi.org/10.1007/s12263-011-0222-1
   PubMed Web of Science ®Google Scholar
• Pesakhov S, Nachliely M, Barvish Z, Aqaqe N, Schwartzman B, Voronov E, Sharoni Y, Studzinski GP, Fishman D, Danilenko M. Cancer-selective cytotoxic Ca2+ overload in acute myeloid leukemia cells and attenuation of disease progression in mice by synergistically acting polyphenols curcumin and carnosic acid. Oncotarget 2016; 7(22):31847-31861; PMID:26870993; http://dx.doi.org/10.18632/oncotarget.7240
   PubMed Web of Science ®Google Scholar
• Weng Q, Ren L, Guo L, Hu Y, Zhou H, Bao Y, Chen L, Liang G, Wang Y, Ruan J. Curcumin analogue, A13, exhibits anti-leukemia effect via inhibiting STAT3. Tumour Biol 2016; 37(7):9959-66; PMID:26815506; http://dx.doi.org/10.1007/s13277-016-4861-0
   PubMed Web of Science ®Google Scholar
• Taverna S, Giallombardo M, Pucci M, Flugy A, Manno M, Raccosta S, Rolfo C, De Leo G, Alessandro R. Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21. Oncotarget 2015; 6:21918-33; PMID:26116834; http://dx.doi.org/10.18632/oncotarget.4204
   PubMed Web of Science ®Google Scholar
• Wu L, Yu J, Chen R, Liu Y, Lou L, Wu Y, Huang L, Fan Y, Gao P, Huang M, et al. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells. Clin Cancer Res 2015; 21:833-43; PMID:25501124; http://dx.doi.org/10.1158/1078-0432.CCR-13-3317
   PubMed Web of Science ®Google Scholar
• Vendetti FP, Rudin CM. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opin Biol Ther 2013; 13:1273-85; PMID:23859704; http://dx.doi.org/10.1517/14712598.2013.819337
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010; 7:433-44; PMID:20551943; http://dx.doi.org/10.1038/nrclinonc.2010.87
   PubMed Web of Science ®Google Scholar
• Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB, Cardoso MC, Leonhardt H. Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods 2005; 2:751-6; PMID:16179921; http://dx.doi.org/10.1038/nmeth794
   PubMed Web of Science ®Google Scholar
• Fu N, Drinnenberg I, Kelso J, Wu JR, Paabo S, Zeng R, Khaitovich P. Comparison of protein and mRNA expression evolution in humans and chimpanzees. PLoS One 2007; 2:e216; PMID:17299596; http://dx.doi.org/10.1371/journal.pone.0000216
   PubMed Web of Science ®Google Scholar
• Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003; 4:117; PMID:12952525; http://dx.doi.org/10.1186/gb-2003-4-9-117
   PubMed Web of Science ®Google Scholar
• Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE. Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res 2000; 60:6890-4; PMID:11156387
   PubMed Web of Science ®Google Scholar
• Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, Herman JG, Baylin SB. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006; 2:e40; PMID:16596166; http://dx.doi.org/10.1371/journal.pgen.0020040
   PubMed Web of Science ®Google Scholar
• Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estécio MR, Issa JP. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 2012; 72:1170-81; PMID:22219169; http://dx.doi.org/10.1158/0008-5472.CAN-11-3248
   PubMed Web of Science ®Google Scholar
• Tie F, Banerjee R, Stratton CA, Prasad-Sinha J, Stepanik V, Zlobin A, Diaz MO, Scacheri PC, Harte PJ. CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. Development 2009; 136:3131-41; PMID:19700617; http://dx.doi.org/10.1242/dev.037127
   PubMed Web of Science ®Google Scholar
• Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114:2764-73; PMID:19546476; http://dx.doi.org/10.1182/blood-2009-02-203547
   PubMed Web of Science ®Google Scholar
• Szyf M. DNA methylation and demethylation as targets for anticancer therapy. Biochemistry (Mosc) 2005; 70:533-49; PMID:15948707; http://dx.doi.org/10.1007/s10541-005-0147-7
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate 2007; 67:1781-90; PMID:17929270; http://dx.doi.org/10.1002/pros.20665
   PubMed Web of Science ®Google Scholar
• Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 1994; 54:1766-71; PMID:7511051
   PubMed Web of Science ®Google Scholar
• Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma 2007; 48:1676-95; PMID:17786703; http://dx.doi.org/10.1080/10428190701493910
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Jaekel N, Niederwieser D. The role of hypomethylating agents in the treatment of elderly patients with AML. J Geriatr Oncol 2014; 5:89-105; PMID:24484723; http://dx.doi.org/10.1016/j.jgo.2013.08.004
   PubMed Web of Science ®Google Scholar